-
1
-
-
33646852746
-
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
-
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
-
(2006)
Ann Intern Med
, vol.144
, pp. 705-714
-
-
Armstrong, G.L.1
Wasley, A.2
Simard, E.P.3
McQuillan, G.M.4
Kuhnert, W.L.5
Alter, M.J.6
-
2
-
-
84857144025
-
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007
-
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
-
(2012)
Ann Intern Med
, vol.156
, pp. 271-278
-
-
Ly, K.N.1
Xing, J.2
Klevens, R.M.3
Jiles, R.B.4
Ward, J.W.5
Holmberg, S.D.6
-
3
-
-
33846403737
-
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
-
Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
-
(2007)
J Viral Hepat
, vol.14
, pp. 107-115
-
-
Deuffic-Burban, S.1
Poynard, T.2
Sulkowski, M.S.3
Wong, J.B.4
-
4
-
-
0033545541
-
Rising incidence of hepatocellular carcinoma in the United States
-
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
-
(1999)
N Engl J Med
, vol.340
, pp. 745-750
-
-
El-Serag, H.B.1
Mason, A.C.2
-
6
-
-
84879098848
-
-
Waiting list candidates [Computer file]. Organ Procurement and Transplantation Network (OPTN). U.S. Dept. of Health and Human Services, Public Health Service, Bureau of Health Resources Development, Division of Organ Transplantation
-
Waiting list candidates [Computer file]. Organ Procurement and Transplantation Network (OPTN). U.S. Dept. of Health and Human Services, Public Health Service, Bureau of Health Resources Development, Division of Organ Transplantation; 2011.
-
(2011)
-
-
-
7
-
-
13644267743
-
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security
-
Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21: 55-65.
-
(2005)
Int J Technol Assess Health Care
, vol.21
, pp. 55-65
-
-
Siebert, U.1
Sroczynski, G.2
-
8
-
-
0030720484
-
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
-
Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
-
(1997)
Ann Intern Med
, vol.127
, pp. 855-865
-
-
Bennett, W.G.1
Inoue, Y.2
Beck, J.R.3
Wong, J.B.4
Pauker, S.G.5
Davis, G.L.6
-
9
-
-
0034959828
-
Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden
-
Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870-876.
-
(2001)
Scand J Gastroenterol
, vol.36
, pp. 870-876
-
-
Sennfalt, K.1
Reichard, O.2
Hultkrantz, R.3
Wong, J.B.4
Jonsson, D.5
-
10
-
-
33746595252
-
Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
-
Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006; 38: 497-505.
-
(2006)
Scand J Infect Dis
, vol.38
, pp. 497-505
-
-
Bernfort, L.1
Sennfalt, K.2
Reichard, O.3
-
11
-
-
0033799722
-
Estimating future hepatitis C morbidity, mortality, and costs in the United States
-
Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
-
(2000)
Am J Public Health
, vol.90
, pp. 1562-1569
-
-
Wong, J.B.1
McQuillan, G.M.2
McHutchison, J.G.3
Poynard, T.4
-
12
-
-
0038352047
-
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
-
Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
-
(2003)
JAMA
, vol.290
, pp. 228-237
-
-
Salomon, J.A.1
Weinstein, M.C.2
Hammitt, J.K.3
Goldie, S.J.4
-
13
-
-
0030671562
-
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
-
Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-874.
-
(1997)
Ann Intern Med
, vol.127
, pp. 866-874
-
-
Kim, W.R.1
Poterucha, J.J.2
Hermans, J.E.3
Therneau, T.M.4
Dickson, E.R.5
Evans, R.W.6
-
14
-
-
34447500595
-
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels
-
Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 2007; 70: 177-187.
-
(2007)
Acta Gastroenterol Belg
, vol.70
, pp. 177-187
-
-
Gerkens, S.1
Nechelput, M.2
Annemans, L.3
Peraux, B.4
Beguin, C.5
Horsmans, Y.6
-
15
-
-
75149163334
-
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression
-
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
-
(2010)
Gastroenterology
, vol.138
, pp. 513-521
-
-
Davis, G.L.1
Alter, M.J.2
El-Serag, H.3
Poynard, T.4
Jennings, L.W.5
-
16
-
-
79958733325
-
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
-
Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31( Suppl 2): 4-17.
-
(2011)
Liver Int
, vol.31
, Issue.SUPPL. 2
, pp. 4-17
-
-
Kershenobich, D.1
Razavi, H.A.2
Cooper, C.L.3
Alberti, A.4
Dusheiko, G.M.5
Pol, S.6
-
17
-
-
84856239637
-
All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective
-
McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-546.
-
(2011)
J Manag Care Pharm
, vol.17
, pp. 531-546
-
-
McAdam-Marx, C.1
McGarry, L.J.2
Hane, C.A.3
Biskupiak, J.4
Deniz, B.5
Brixner, D.I.6
-
18
-
-
84857373298
-
Economic burden of hepatitis C-associated diseases in the United States
-
El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012; 19: 153-160.
-
(2012)
J Viral Hepat
, vol.19
, pp. 153-160
-
-
El Khoury, A.C.1
Wallace, C.2
Klimack, W.K.3
Razavi, H.4
-
19
-
-
84868125609
-
-
University of California, Berkeley
-
Human mortality database, University of California, Berkeley; 2012.
-
(2012)
Human mortality database
-
-
-
20
-
-
0032731788
-
Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C
-
Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999; 30: 1318-1324.
-
(1999)
HEPATOLOGY
, vol.30
, pp. 1318-1324
-
-
Younossi, Z.M.1
Singer, M.E.2
McHutchison, J.G.3
Shermock, K.M.4
-
21
-
-
73149113990
-
Public health impact of antiviral therapy for hepatitis C in the United States
-
Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
-
(2009)
HEPATOLOGY
, vol.50
, pp. 1750-1755
-
-
Volk, M.L.1
Tocco, R.2
Saini, S.3
Lok, A.S.4
-
22
-
-
84879123400
-
-
Centers for Disease Control and Prevention. Hepatitis surveillance. Hepatitis surveillance/Center for Disease Control Sept. 1 (Report 61).
-
Centers for Disease Control and Prevention. Hepatitis surveillance. Hepatitis surveillance/Center for Disease Control 2006 Sept. 1 (Report 61).
-
(2006)
-
-
-
23
-
-
33947519044
-
Surveillance for acute viral hepatitis-United States, 2005
-
Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 2007; 56: 1-24.
-
(2007)
MMWR Surveill Summ
, vol.56
, pp. 1-24
-
-
Wasley, A.1
Miller, J.T.2
Finelli, L.3
-
24
-
-
40949100835
-
Surveillance for acute viral hepatitis-United States, 2006
-
Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
-
(2008)
MMWR Surveill Summ
, vol.57
, pp. 1-24
-
-
Wasley, A.1
Grytdal, S.2
Gallagher, K.3
-
25
-
-
67649297326
-
Surveillance for acute viral hepatitis-United States, 2007
-
Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
-
(2009)
MMWR Surveill Summ
, vol.58
, pp. 1-27
-
-
Daniels, D.1
Grytdal, S.2
Wasley, A.3
-
28
-
-
22044433989
-
Natural history of hepatitis C
-
Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
-
(2005)
Clin Liver Dis
, vol.9
, pp. 383-398
-
-
Thomas, D.L.1
Seeff, L.B.2
-
30
-
-
84879116345
-
-
National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
-
National Health and Nutrition Examination Survey Data, 2009-2010 Centers for Disease Control and Prevention. National Center for Health Statistics. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
-
(2012)
-
-
-
31
-
-
0036690660
-
Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population
-
Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-979.
-
(2002)
Transfusion
, vol.42
, pp. 975-979
-
-
Dodd, R.Y.1
Notari, E.P.2
Stramer, S.L.3
-
32
-
-
77954324675
-
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing
-
Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504.
-
(2010)
Transfusion
, vol.50
, pp. 1495-1504
-
-
Zou, S.1
Dorsey, K.A.2
Notari, E.P.3
Foster, G.A.4
Krysztof, D.E.5
Musavi, F.6
-
33
-
-
33846408285
-
Injection drug users in the United States, 1979-2002: an aging population
-
Armstrong GL. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 2007; 167: 166-173.
-
(2007)
Arch Intern Med
, vol.167
, pp. 166-173
-
-
Armstrong, G.L.1
-
34
-
-
34547428001
-
Predictors of response of US veterans to treatment for the hepatitis C virus
-
Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. HEPATOLOGY 2007; 46: 37-47.
-
(2007)
HEPATOLOGY
, vol.46
, pp. 37-47
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Mole, L.A.4
-
35
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
Muir, A.J.4
Galler, G.W.5
McCone, J.6
-
36
-
-
0033022946
-
Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study
-
Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874-880.
-
(1999)
Gut
, vol.44
, pp. 874-880
-
-
Bellentani, S.1
Pozzato, G.2
Saccoccio, G.3
Crovatto, M.4
Croce, L.S.5
Mazzoran, L.6
-
37
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
38
-
-
0036829652
-
Fibrosis and disease progression in hepatitis C
-
Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002; 36( 5 Suppl 1): S47-S56.
-
(2002)
HEPATOLOGY
, vol.36
, Issue.5 SUPPL. 1
-
-
Marcellin, P.1
Asselah, T.2
Boyer, N.3
-
39
-
-
0032924020
-
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
-
Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. HEPATOLOGY 1999; 29: 1215-1219.
-
(1999)
HEPATOLOGY
, vol.29
, pp. 1215-1219
-
-
Hourigan, L.F.1
Macdonald, G.A.2
Purdie, D.3
Whitehall, V.H.4
Shorthouse, C.5
Clouston, A.6
-
40
-
-
78650823246
-
Impact of a sustained virological response on the long-term outcome of hepatitis C
-
Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31( Suppl 1): 18-22.
-
(2011)
Liver Int
, vol.31
, Issue.SUPPL. 1
, pp. 18-22
-
-
Alberti, A.1
-
41
-
-
79961199944
-
Hepatitis C virus infection in the United States: an estimate of true prevalence
-
Chak E, Talal A, Sherman KE, Schiff E, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011; 31: 1090-1101.
-
(2011)
Liver Int
, vol.31
, pp. 1090-1101
-
-
Chak, E.1
Talal, A.2
Sherman, K.E.3
Schiff, E.4
Saab, S.5
-
42
-
-
84867288022
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
-
(2012)
MMWR Recomm Rep
, vol.61
, pp. 1-32
-
-
-
43
-
-
84859947750
-
Economic model of a birth cohort screening program for hepatitis C virus
-
McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. HEPATOLOGY 2012; 55: 1344-1355.
-
(2012)
HEPATOLOGY
, vol.55
, pp. 1344-1355
-
-
McGarry, L.J.1
Pawar, V.S.2
Panchmatia, H.R.3
Rubin, J.L.4
Davis, G.L.5
Younossi, Z.M.6
-
44
-
-
0027068086
-
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team
-
Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
-
(1992)
N Engl J Med
, vol.327
, pp. 1899-1905
-
-
Alter, M.J.1
Margolis, H.S.2
Krawczynski, K.3
Judson, F.N.4
Mares, A.5
Alexander, W.J.6
-
45
-
-
0033023854
-
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
-
Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999; 29: 908-914.
-
(1999)
HEPATOLOGY
, vol.29
, pp. 908-914
-
-
Villano, S.A.1
Vlahov, D.2
Nelson, K.E.3
Cohn, S.4
Thomas, D.L.5
-
46
-
-
49649118223
-
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression
-
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. HEPATOLOGY 2008; 48: 418-431.
-
(2008)
HEPATOLOGY
, vol.48
, pp. 418-431
-
-
Thein, H.H.1
Yi, Q.2
Dore, G.J.3
Krahn, M.D.4
-
47
-
-
62549087194
-
-
Bethesda, MD, National Cancer Institute, SEER Program.
-
Ries LAG, Young GL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. [NIH Pub.No.07-6215]. 2007. Bethesda, MD, National Cancer Institute, SEER Program.
-
(2007)
SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. [NIH Pub.No.07-6215]
-
-
Ries, L.A.G.1
Young, G.L.2
Keel, G.E.3
Eisner, M.P.4
Lin, Y.D.5
Horner, M.-J.6
|